The third group included inhibitors with minimal or no effect on these cells, such as PRC2 inhibitors and class II HDAC inhibitors, suggesting they are unsuitable for treating MLL-r leukemia, irrespective of SETD2 mutation status. Here, HDAC9 is linked to leukemia.